FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial
Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group
Peter Borchmann
09:15 – 10:15
Room: Großer Saal
Scientific SessionSpecial Situations in HL
Richard Hoppe
Marie Jose Kersten
09:15–09:35
HL in Pregnancy
Daan Dierickx
09:35–09:55
HIV-positive HL
Otavio Baiocchi
09:55–10:15
alloSCT in the era of anti-PD1
Anna Sureda
10:30 – 12:00
Room: Großer Saal
Scientific SessionGenomics, Biology and Microenvironment
Single-cell RNA sequencing reveals the interplay between circulating CD4 T cells, B cells and cancer-associated monocytes in classic Hodgkin lymphoma treated with PD-1 blockade
Julia Paczkowska
12:15 – 13:45
Room: Großer Saal
Satellite Symposium
(by Takeda)
Bridging the gap between efficacy and toxicity in the frontline treatment of stage IV Hodgkin lymphoma
Graham Collins
Alex Herrera
Pier Luigi Zinzani
12:15–12:20
Welcome and introduction
Graham Collins
12:20–12:30
Hot off the press: The latest data for the frontline treatment of patients with Stage IV CD30+ Hodgkin Lymphoma from ECHELON-1
Graham Collins
12:30–13:30
Bridging the gap: Balancing efficacy and toxicity in three challenging case studies (A debate and audience discussion with our panel)
Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma
Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)